808744-34-5

Basic information

• Product Name: IMIDAZO[1,2-A]PYRIDINE, 7-BROMO-
• Synonyms: IMIDAZO[1,2-A]PYRIDINE, 7-BROMO-;7-Bromoimidazo[1,2-a]pyridine;7-bromoH-imidazo[1,2-a]pyridine hydrochloride;7-Bromoimidazo[1,2-a]pyri...;7-broMoH-iMidazo[1,2-a]pyridine;7-bromoimidazo[1,2-a]pyridine HCL
• CAS NO: 808744-34-5
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.03
• EINECS: 1533716-785-6
• Mol File: 808744-34-5.mol
• Article Data: 18

Chemical Properties

• Melting Point: 118-120℃
• Appearance: /
• Density: 1.69
• Refractive Index: 1.688
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.15±0.50(Predicted)
• CAS DataBase Reference: IMIDAZO[1,2-A]PYRIDINE, 7-BROMO-(CAS DataBase Reference)
• NIST Chemistry Reference: IMIDAZO[1,2-A]PYRIDINE, 7-BROMO-(808744-34-5)
• EPA Substance Registry System: IMIDAZO[1,2-A]PYRIDINE, 7-BROMO-(808744-34-5)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 808744-34-5(Hazardous Substances Data)

Usage

General Description

Imidazo[1,2-a]pyridine, 7-bromo- is a chemical compound with the molecular formula C8H6BrN3. It is a heterocyclic compound containing an imidazole ring fused to a pyridine ring, with a bromine atom at the 7th position. This chemical structure is commonly used as a building block or intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds. It has properties that make it useful in the development of various drug candidates, including anticancer, antibacterial, and antifungal agents. Imidazo[1,2-a]pyridine, 7-bromo- is a versatile compound with potential applications in medicinal chemistry and drug discovery efforts.

InChI:InChI=1/C7H5BrN2/c8-6-1-3-10-4-2-9-7(10)5-6/h1-5H

Upstream product

• 107-20-0 2-chloroethanal 
• 84249-14-9 2-amino-4-bromopyridine 

Downstream Products

• 908267-70-9 7-(pyridin-2-yl)imidazo[1,2-a]pyridine 
• 1146615-82-8 3-imidazo[1,2-a]pyridine-7-yl-N-methyl-benzamide 
• 1246184-55-3 7-bromo-3-iodo-imidazo[1,2-a]pyridine 
• 1276023-79-0 (S)-3-(H-imidazo[1,2-a]pyridin-7-yl)-4-(4-propoxyphenyl)oxazolidin-2-one 
• 1276023-83-6 3-(imidazo[1,2-a]pyridin-7-yl)-4-(4-propoxyphenyl)-1,3-oxazinan-2-one 
• 1202701-98-1 (S)-(N-3-(3-fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-2-oxo-5-oxazolidinyl)methylacetamide 
• 1202703-04-5 (R)-3-(3-fluoro-4-(imidazo[1,2-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one 
• 908268-52-0 7-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)imidazo[1,2-a]pyridine 
• 896139-85-8 imidazo[1,2-a]pyridine-7-ol 
• 1036991-50-0 1-(imidazo[1,2-a] pyridin-7-yl)ethan-1-one 
• 421595-81-5 imidazo[1,2-a]pyridin-7-amine 

Relevant articles and documents

SALT INDUCIBLE KINASE INHIBITORS

The present application provides compounds that modulate the activity of one or more salt inducible kinases (SIKs). Pharmaceutical composition and methods of treating diseases associated with abnormal expression and/or activity of one or more SIKs are also provided.

Heterocyclic kinase inhibitor

The invention belongs to the technical field of medicines, and particularly relates to a heterocyclic DNA-PK kinase inhibitor compound shown as a general formula (I), a pharmaceutically acceptable salt and an isomer thereof, a pharmaceutical composition and preparation containing the compound, the pharmaceutically acceptable salt and the isomer thereof, a method for preparing the compound, the pharmaceutically acceptable salt and the isomer thereof, and application of the compound, the pharmaceutically acceptable salt and the isomer thereof.

Design, synthesis, and structure activity relationship (SAR) studies of novel imidazo[1,2-a] pyridine derivatives as Nek2 inhibitors

Never in mitosis (NIMA) related kinase 2 (Nek2) is involved in multiple cellular processes such as cell cycle checkpoint regulation, cell division, DNA damage response and cell apoptosis. Nek2 has been reported to be overexpressed in various tumors and correlated with poor prognosis. Herein, a series of imidazo[1,2-a] pyridines Nek2 inhibitors were designed, synthesized, and their biological activities were investigated. Besides, structure activity relationship analysis of these compounds were performed in the MGC-803 cell. The screening results are promising, and compound 28e shows good proliferation inhibitory activity with an IC50 of 38 nM. The results would be helpful to design and develop more effective Nek2 inhibitors for the treatment of gastric cancer.